

Proto-Oncogenic Role of Mutant *IDH2* in Leukemia Initiation and Maintenance

Lev M. Kats,^{1,9} Markus Reschke,^{1,9} Riccardo Tauli,¹ Olga Pozdnyakova,² Kerri Burgess,¹ Parul Bhargava,¹ Kimberly Straley,³ Rahul Karnik,^{4,5,6} Alexander Meissner,^{4,5,6} Donald Small,⁷ Shinsan M. Su,³ Katharine Yen,³ Jiangwen Zhang,⁸ and Pier Paolo Pandolfi^{1,*}

¹Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

²Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA

³Agios Pharmaceuticals, Cambridge, MA 02139, USA

⁴Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA

⁵Harvard Stem Cell Institute, Cambridge, MA 02138, USA

⁶Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA

⁷Oncology and Pediatrics, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA

⁸School of Biological Sciences, The University of Hong Kong, Hong Kong SAR

⁹These authors contributed equally to this work

*Correspondence: ppandolfi@bidmc.harvard.edu
<http://dx.doi.org/10.1016/j.stem.2013.12.016>

SUMMARY

Mutations in the metabolic enzymes isocitrate dehydrogenase-1 (IDH1) and IDH2 that produce the oncometabolite D-2-hydroxyglutarate (2-HG) occur frequently in human acute myeloid leukemia (AML). 2-HG modulates numerous biological pathways implicated in malignant transformation, but the contribution of mutant IDH proteins to maintenance and progression of AML in vivo is currently unknown. To answer this crucial question we have generated transgenic mice that express *IDH2*^{R140Q} in an on/off- and tissue-specific manner using a tetracycline-inducible system. We found that *IDH2*^{R140Q} can cooperate with overexpression of HoxA9 and Meis1a and with mutations in FMS-like tyrosine kinase 3 (FLT3) to drive acute leukemia in vivo. Critically, we show that genetic deinduction of mutant *IDH2* in leukemic cells in vivo has profound effects on their growth and/or maintenance. Our data demonstrate the proto-oncogenic role of mutant *IDH2* and support its relevance as a therapeutic target for the treatment of human AML.

INTRODUCTION

The isocitrate dehydrogenase (IDH) family of enzymes catalyzes the oxidative decarboxylation of isocitrate to α -ketoglutarate (α -KG) and carbon dioxide. Mutations in active site arginines of IDH1 and IDH2 have recently been identified in ~20% of acute myeloid leukemias (AMLs) (Cancer Genome Atlas Research Network, 2013; Mardis et al., 2009), as well as in a range of other malignancies including glioblastoma, chondrosarcoma, and prostate cancer (Amary et al., 2011; Kang et al., 2009;

Parsons et al., 2008). Mutations confer on the enzymes a novel ability to produce D-2-hydroxyglutarate (2-HG), a molecule that is structurally similar to α -KG and can act as a competitive inhibitor of α -KG-dependent dioxygenases that in turn regulate a wide array of biological processes including DNA and histone demethylation, collagen maturation, and the hypoxic response (Dang et al., 2009; Ward et al., 2010; Xu et al., 2011). In AML, patient *IDH* mutations are associated with a normal karyotype and often co-occur with other genetic lesions including internal tandem duplication in FMS-like tyrosine kinase 3 (*FIt3*^{ITD}) and mutations that promote the cytoplasmic localization of Nucleophosmin 1 (*NPMc+*) (Patel et al., 2012).

Mutant IDH proteins have been proposed as attractive drug targets and molecules that block the production of 2-HG have recently been reported (Popovici-Muller et al., 2012; Wang et al., 2013). Expression of mutant IDH1 or IDH2 proteins is sufficient to block differentiation of hematopoietic cells in vitro as well as in vivo and can be reversed by inhibitor treatment (Figueroa et al., 2010; Losman et al., 2013; Sasaki et al., 2012; Wang et al., 2013). Retroviral transduction of *IDH* mutations in combination with additional oncogenes into primary mouse bone marrow cells followed by transplantation have been shown to drive leukemia development (Chaturvedi et al., 2013; Chen et al., 2013); however, the central question of whether mutant IDH1 and IDH2 proteins are required for leukemia maintenance in vivo remains yet to be answered. Herein we address this question through the generation and characterization of transgenic murine models where expression of *IDH2*^{R140Q} is conditional and regulatable.

RESULTS

Generation and Characterization of *IDH2*^{R140Q} Transgenic Mice

To develop a mouse model of *IDH2*^{R140Q} mutation that has the capacity to be both tissue-specific and on/off-inducible, we




Figure 1. *IDH2^{R140Q-t}* Mice Demonstrate Extramedullary Hematopoiesis Characterized by Spleen Enlargement and Expansion of Hematopoietic Stem/Progenitor Cells

(A) Schematic depicting the strategy for generation of an inducible *IDH2^{R140Q}* allele in the mouse. Following Flp-mediated recombination, the *IDH2^{R140Q}* cDNA flanked by a tetracycline response element (*TRE*) and a protamine-1 poly-A cassette is integrated into the *ColA1* locus. The *PGK* promoter drives hygromycin resistance, allowing selection of integrants.

(B) 2-HG in BM MNCs measured by LC-MS following 8 weeks of transgene induction.

(C) Representative flow cytometry analysis of bone marrow mononuclear cells and splenocytes from mice treated with doxycycline for 8 weeks or 7 months. Numbers indicate cells within the gate as a percentage of all living cells in the sample.

(legend continued on next page)

used the tetracycline response element (TRE)/tetracycline transactivator (tTA) system. Briefly, the *IDH2*^{R140Q} cDNA was cloned downstream of a TRE followed by a protamine-1 polyA cassette (Fisher et al., 2001) and targeted into the mouse *Collagen A1* locus of C2-embryonic stem cells (ESCs) using Flp-recombinase-mediated genomic integration (Beard et al., 2006) (Figures 1A and S1A available online). Chimeric mice harboring the inducible *IDH2*^{R140Q} allele were backcrossed into the C57BL/6 background and then crossed to mice that constitutively express the M2 reverse tTA from the *ROSA26* locus (*ROSA26-M2*) (Hochedlinger et al., 2005). Compound *IDH2*^{R140Q+/-}; *ROSA26-M2*^{+/-} (hereafter referred to as *IDH2*^{R140Q-t}) were born at Mendelian ratios (data not shown) and appeared normal and were compared to single transgenic (i.e., *IDH2*^{R140Q+/-} or *ROSA26-M2*^{+/-}) or wild-type littermates (hereafter referred to as controls).

Due to the documented frequency of *IDH* mutations in AML patients (Cancer Genome Atlas Research Network, 2013; Mardis et al., 2009; Patel et al., 2012), we chose to focus specifically on the hematopoietic system of our transgenic mice. *IDH2*^{R140Q} expression was induced in animals at ~3 weeks of age by introducing doxycycline in the chow. Quantitative reverse-transcriptase PCR (qRT-PCR) using primers specific for the transgene confirmed *IDH2*^{R140Q} mRNA expression in both mature and immature bone marrow cells from *IDH2*^{R140Q-t} animals (Figure S1C). Western blot analysis using an antibody that recognizes both the mutant *IDH2*^{R140Q} and the endogenous wild-type *IDH2* proteins revealed that the total levels of *IDH2* in the bone marrow of *IDH2*^{R140Q-t} animals were increased by approximately 2-fold in comparison with controls (Figure S1B). Because the level of endogenous *Idh2* mRNA was unaffected by transgene expression (data not shown), these data suggest that the ratio of wild-type to mutant protein in our system is approximately 1:1.

The *IDH2*^{R140Q} mutation, as well as other cancer-associated mutations in *IDH1* and *IDH2*, has been shown to lead to the production of the oncometabolite 2-hydroxyglutarate (2-HG) (Dang et al., 2009; Ward et al., 2010). 2-HG accumulates in *IDH* mutant cancer cells at low mM concentrations and can also be detected in the serum of patients with mutant *IDH* AML (Gross et al., 2010). We used liquid chromatography-mass spectrometry (LC-MS) to quantify 2-HG in both serum (Figure S1E) and isolated bone marrow mononuclear cells (BM MNCs) (Figure 1B) from our mice. As expected, high levels of 2-HG were detected only in *IDH2*^{R140Q-t} animals.

To confirm that transgene expression and 2-HG production could be reversed in vivo, mice that had been on a doxycycline diet for a period of 8 weeks were placed on a diet without doxycycline for 2 weeks. Following this period of deinduction, both transgene expression and serum 2-HG levels dropped significantly and returned almost to basal levels (Figures S1D and S1E). Together these data demonstrate that we have generated an inducible model of the cancer-associated *IDH2*^{R140Q} mutation in which transgene expression and the consequent

production of 2-HG can be regulated by administration of doxycycline.

Expression of *IDH2*^{R140Q} in the Bone Marrow Results in Aberrant Hematopoiesis in Vivo

In order to establish the impact of *IDH2*^{R140Q} expression on normal hematopoietic stem/progenitor cells (HSPCs) as well as lineage development in vivo, we undertook a detailed analysis of hematopoiesis in our transgenic animals. Eight weeks after transgene induction, *IDH2*^{R140Q-t} and control peripheral blood cell counts showed no differences (Figures S1F–S1H). Likewise, there were no alterations in the numbers of hematopoietic stem cells, myeloid progenitors, or mature B, T, or myeloid cells in the bone marrow (Figures S1I–S1O). However, the spleens of *IDH2*^{R140Q-t} mice were approximately 1.3-fold larger (99.05 ± 4.851 mg versus 77.69 ± 4.54 mg for the controls; *p* < 0.005, Student's *t* test) (Figure 1D) and fluorescence-activated cell sorting (FACS) analysis revealed significant extramedullary hematopoiesis, as evidenced by increased numbers of cKit⁺Sca1⁺Lin⁻ (KSL) HSPCs (Figures 1C and 1E).

To assess the longer-term effect of *IDH2*^{R140Q} mutation, we analyzed mice following 7 months of continuous transgene induction. In addition to the changes observed at earlier time points, *IDH2*^{R140Q-t} mice also had increased numbers of KSL cells in the bone marrow compared to controls (Figures 1C and 1F). Five out of ten mutants also displayed an expansion of the long-term hematopoietic stem cell (LT-HSC) compartment (CD48⁻CD150⁺KSL), although overall this trend was not statistically significant (Figures 1C and 1G). To extend our findings we performed competitive bone marrow transplantation assays in which sorted KSL cells from *IDH2*^{R140Q-t} and control mice (CD45.2⁺) were transplanted into sublethally irradiated recipients (CD45.1⁺). In this assay, *IDH2*^{R140Q-t} HSPCs showed no difference in repopulation capacity compared to control HSPCs for at least 16 weeks after transplantation (Figures S1P–S1S).

IDH2^{R140Q} Expression in HSPCs Drives a Block of Erythroid Differentiation in Vitro

Deregulated hematopoietic differentiation is frequently observed in AML and 2-HG has been shown to induce a partial block of differentiation in the erythroid leukemia cell line TF-1 (Losman et al., 2013; Wang et al., 2013). We therefore sought to investigate the effect of *IDH2*^{R140Q} on differentiation of primary hematopoietic cells using a well-established methylcellulose differentiation assay. Following 8 weeks of transgene induction, we sorted KSL cells from *IDH2*^{R140Q-t} and control mice and performed colony-forming unit (CFU) assays using semisolid medium with cytokines formulated to drive differentiation into the myeloid and erythroid lineages (MethoCult GF M3434). In the initial experiments, doxycycline was added to the medium to ensure continued transgene expression throughout the differentiation process. Strikingly, we observed a potent block of differentiation in *IDH2*^{R140Q-t} HSPCs compared with controls (Figure 2A).

(D) Spleen weights of mice following 8 weeks of doxycycline treatment.

(E) Percentage of cKit⁺Sca1⁺Lin⁻ (KSL) cells in the spleens of mice following 8 weeks of doxycycline treatment.

(F) Percentage of KSL cells in the bone marrow of mice following 7 months of doxycycline treatment.

(G) Percentage of CD48⁻CD150⁺KSL hematopoietic stem cells in the bone marrow of mice following 7 months of doxycycline treatment.

Error bars, mean ± SEM; *p* value calculated using a two-tailed unpaired Student's *t* test. See also Figure S1.




Figure 2. *IDH2^{R140Q-t}* Induces a Block of Erythroid Differentiation in KSL Cells That Is Reversible by Genetic Deinduction of the Transgene and by a Specific Inhibitor of Mutant IDH2

(A) Methylcellulose CFU-GEMM assay using KSL cells sorted from *IDH2^{R140Q-t}* or control mice following 8 weeks of doxycycline treatment. Doxycycline was added to the media to maintain transgene expression throughout the differentiation process (n = 7 biological replicates/group).

(B) Methylcellulose CFU-GEMM assay done as in (A) but with or without adding doxycycline to the medium (n = 3 biological replicates/group).

(C and D) Methylcellulose CFU-GEMM assay done as in (A), with doxycycline in the medium and with or without the mutant IDH2 inhibitor AGI-6780. 2-HG was quantified by LC-MS in cells collected from the assay after 7 days of culture. b.q.l., below quantitative limit (C). Colonies were scored (n = 4 biological replicates/group) in (D).

Error bars, mean ± SEM; p value calculated using a two-tailed unpaired Student's t test. See also Figure S2.

Importantly, while the number of myeloid colonies (M, G/GM) was unaffected, the number of erythroid colonies was severely reduced (19.5 ± 1.3 in the controls versus 3.6 ± 0.9 in *IDH2^{R140Q-t}*; $p < 0.0001$, Student's t test). Notably, when cells from the first plating were collected and replated, *IDH2^{R140Q-t}* cells formed more colonies in the second plating when compared with controls. *IDH2^{R140Q-t}* cells could also be serially replated at least five times, whereas control cells no longer formed colonies after the third plating (Figure S2A).

To determine if the block of differentiation induced by *IDH2* mutation in our model can be reversed, we performed a series of experiments using both genetic and pharmacological inactivation of *IDH2^{R140Q}*. First, we compared differentiation of *IDH2^{R140Q-t}* and control KSL cells in the presence or absence of doxycycline. We sorted cells from mice following 8 weeks of in vivo transgene induction and then cultured them in CFU assays either with or without doxycycline. We confirmed that within 72 hr of doxycycline-free culture, transgene expression

was efficiently silenced (Figure S2B). Excitingly, upon silencing *IDH2^{R140Q}*, differentiation of mutant cells was restored to wild-type levels, demonstrating that continued expression of the mutant protein is required for the block of differentiation (Figure 2B).

Next we used a specific inhibitor of *IDH2^{R140Q}* (AGI-6780) that has recently been shown to block production of 2-HG by the mutant protein (Wang et al., 2013). We confirmed that in our system 5 μ M of the compound was able to reduce 2-HG production in mutant cells by ~75% (1.29 ± 0.29 mM in untreated cells versus 0.34 ± 0.04 mM in AGI-6780-treated cells; $p < 0.05$, Student's t test) (Figure 2C). Similar to genetic deinduction, AGI-6780 completely reversed the block of differentiation in *IDH2^{R140Q-t}* KSL cells (Figure 2D). AGI-6780 also reversed aberrant colony formation in the second and third plating (Figure S2C). Taken together our data demonstrate that mutant IDH proteins are sufficient to induce defects in the differentiation of primary hematopoietic cells. Critically, we have shown that




Figure 3. Identification of a Transcriptional Signature Associated with the *IDH2^{R140Q}*-Induced Block of Differentiation

(A and B) Microarray analysis of cells cultured for 3 days in the methylcellulose CFU-GEMM assay ($n \geq 3$ biological replicates/group). Hierarchical clustering of significantly altered genes ($p < 0.05$, fold change > 1.5) is shown. Green, downregulated in *IDH2^{R140Q-t}* cells; red, upregulated in *IDH2^{R140Q-t}* cells (A). Pathway enrichment analysis shows genes that are downregulated in *IDH2^{R140Q-t}* cells (green) or upregulated (red) in *IDH2^{R140Q-t}* cells. The significance of the enrichment for each pathway (based on the false discovery rate q value) is proportional to the size of the gray box (i.e., the larger the gray box, the more significant the enrichment) (B).

(C) qRT-PCR analysis of cells cultured as in (A) and (B) but with or without AGI-6780. For each of the transcripts examined, pharmacological inhibition of 2-HG production at least partially reverses transcriptional changes in *IDH2^{R140Q-t}* cells. Error bars, mean \pm SEM.

See also Figure S3 and Tables S1, S2, and S3.

these effects are reversible by pharmacological inhibition of 2-HG production by the mutant protein.

Mutant IDH proteins have been demonstrated to affect multiple biological pathways in a cell-context-dependent manner. We sought to explore the transcriptional signature that was associated with the block of erythroid differentiation and so we performed global gene expression microarray analysis. In order to identify genes that are responsible for the block of differentiation, rather than a consequence of it, we sorted KSL cells as previously, but cultured them in MethoCult GF M3434 for only 3 days prior to RNA extraction. At this stage, cells had undergone multiple rounds of division, but $\sim 70\%$ of cells retained an undifferentiated morphology (data not shown). Unsupervised hierarchical clustering revealed

a clear separation of control and *IDH2^{R140Q-t}* samples (Figures 3A and S3A) and gene set enrichment analysis identified multiple pathways that were deregulated in mutant cells (Figure 3B). In particular, *IDH2^{R140Q-t}* cells displayed reduced levels of transcripts activated by the transcription factor GATA1, a master regulator of erythroid differentiation (Fujiwara et al., 1996). Mutant cells also displayed activation of the hypoxia and TNF- α pathways. To validate our microarray findings and to determine whether the transcriptional signature induced by mutant *IDH2* is reversible, we performed qRT-PCR analysis on a subset of genes that were identified as being altered and included control and *IDH2^{R140Q-t}* samples that were treated with AGI-6780 (Figure 3C). For each of the transcripts examined, AGI-6780 at least partially reversed the changes induced




Figure 4. Continued Expression of *IDH2^{R140Q}* Is Required for Proliferation and/or Maintenance of *HoxA9/Meis1a*-Transformed Leukemic Cells

(A) Schematic outlining the strategy for randomized deinduction experiments.

(B) Representative FACS plots of bone marrow from secondary recipients untreated or treated with doxycycline. Continued expression of *IDH2^{R140Q}* is essential for proliferation and/or maintenance of GFP/YFP⁺ leukemic cells and the onset of leukemia.

(C) Percentage of GFP/YFP⁺ cells in the bone marrow of secondary recipients untreated or treated with doxycycline (n = 5 recipients on doxycycline, n = 3 recipients off doxycycline).

(legend continued on next page)

by $IDH2^{R140Q}$. This data further confirms our earlier findings that 2-HG-dependent effects are rapidly reversible. We also sorted megakaryocyte-erythroid progenitors (MEPs) from control and $IDH2^{R140Q-t}$ animals and found that *Bcl6*, identified in our in vitro analysis, was also consistently upregulated in MEPs in vivo (Figure S3B).

Continued Expression of $IDH2^{R140Q}$ Is Essential for Maintenance of *HoxA9/Meis1a*-Transformed Leukemic Cells

IDH mutations have been implicated in cancer but their ability to contribute to the maintenance of established disease in vivo has not been demonstrated. $IDH2^{R140Q-t}$ mice followed for 1 year of continuous doxycycline treatment did not develop leukemia, suggesting that additional genetic events are required for cancer development. This prompted us to investigate a well-established surrogate model of AML using retroviral overexpression of the homeobox proteins *HoxA9* and *Meis1a* (Kroon et al., 1998). KSL cells isolated from $IDH2^{R140Q+/-}; ROSA26-M2^{+/-}$ (hereafter referred to as $IDH2^{R140Qhm-t}$) that had been treated with doxycycline were transduced with retroviruses encoding *HoxA9* (*MSCV-HoxA9-GFP*) and *Meis1a* (*MSCV-Meis1a-YFP*) and transplanted into syngeneic sublethally irradiated recipients (Figure 4A). Following 7 weeks of administering continued doxycycline treatment, we observed an expansion of GFP/YFP⁺ cells in the peripheral blood of primary recipients (not shown), indicating the establishment of an early leukemic or preleukemic state. These animals were then euthanized, GFP/YFP⁺ bone marrow cells were sorted (Figure S4A), and 10⁵ cells were retransplanted into secondary syngeneic recipients. After an initial 3 day period of administering doxycycline treatment to allow engraftment, we performed randomized deinduction with some of the recipients being taken off doxycycline food and thereby experiencing genetic inactivation of $IDH2^{R140Q}$ (Figure 4A).

After 8 weeks, all (5/5) doxycycline-treated secondary recipients developed AML, with their bone marrow being composed almost exclusively of GFP/YFP⁺Mac1⁺ and GFP/YFP⁺Mac1⁺cKit⁺ cells (Figures 4B, 4C, and S4B). All five recipients showed virtually identical disease development (Figure S4B), strongly suggesting that additional stochastic events that may influence the proliferative or immuno-phenotypic properties of the cells had not occurred after transplantation. We confirmed overexpression of *HoxA9* and *Meis1a* in doxycycline-treated recipients using qRT-PCR (Figure S4D). Strikingly, all (3/3) secondary recipients that had been withdrawn from doxycycline had no clearly discernible GFP/YFP⁺ population and normal ratios of myeloid and lymphoid cells, demonstrating that the vast majority of leukemic blasts had been eliminated (Figures 4B, 4C, and S4B).

To determine if a small number of leukemia-initiating cells that was not detectable by FACS remained and could act as a source of disease relapse, we used a PCR assay to detect *MSCV-HoxA9-GFP* and *MSCV-Meis1a-YFP* with primers designed to span introns so as not to amplify endogenous *HoxA9* and *Meis1a* from genomic DNA. Using this assay and following an extended cycling protocol, we could not detect a reservoir of transduced cells in the bone marrow of recipients that had been withdrawn from doxycycline (Figure 4D). These data strongly suggest that all, or at least the vast majority, of leukemic cells, including the leukemia-initiating cell population, were eliminated upon genetic deactivation of $IDH2^{R140Q}$.

Next, we aimed to characterize the kinetics of disease regression upon $IDH2^{R140Q}$ deinduction. As before, sublethally irradiated C57BL/6 recipients were transplanted with 10⁵ GFP/YFP⁺ cells sorted from a preleukemic $IDH2^{R140Qhm-t}/HoxA9/Meis1a$ primary donor. This time, however, all secondary recipients were treated with doxycycline for 14 days, at which point two recipients were sacrificed and FACS analysis revealed that their bone marrow comprised ~50% GFP/YFP⁺ cells (Figure 4E). We then performed randomized deinduction and sacrificed recipients for analysis every 2 weeks. Consistent with what has recently been reported in vitro upon pharmacological inhibition of $IDH2^{R140Q}$ in human and mouse AML cells (Chen et al., 2013; Wang et al., 2013), animals withdrawn from doxycycline treatment initially showed a hyperproliferation of GFP/YFP⁺ leukemic cells (Figure 4E; 4 week time point, 2 weeks off doxycycline food), followed by a reduction and elimination. In total, six of eight animals across the two independent experiments that had been withdrawn from doxycycline treatment for at least 4 weeks showed elimination of leukemic cells from the bone marrow and restoration of normal hematopoiesis (Figure S4C).

FACS, morphological, and transcriptional analyses of bone marrow at the 4 week time point suggested that upon $IDH2^{R140Q}$ deinduction, leukemic cells underwent differentiation. Despite having almost twice as many GFP/YFP⁺ cells in the bone marrow at this time point, recipients that had been withdrawn from doxycycline treatment had similar numbers of blasts to doxycycline-treated recipients (Figure 4F), implying a greatly increased ratio of morphologically differentiated to undifferentiated cells within the GFP/YFP⁺ fraction. Similarly, analysis of the stem/progenitor marker cKit showed a reduced ratio of cKit⁺ to cKit⁻ cells upon deinduction (Figure S4E). Finally, we explored a panel of transcripts identified in our microarray analysis, and found that a subset of genes (*Atf3*, *Ptgs2*, and *S100A9*) that were upregulated in $IDH2^{R140Q-t}$ KSL cells undergoing differentiation in vitro were downregulated upon transgene deinduction in vivo in leukemic cells (Figure S4F). Taken together, our data demonstrate that HSPCs, which initially acquire an $IDH2$ mutation and subsequently become transformed by additional genetic events, at

(D) PCR on genomic DNA isolated from BM MNCs of doxycycline-treated and -untreated recipients using primers specific for *MSCV-HoxA9-GFP* and *MSCV-Meis1a-YFP*. Vector (i.e., *MSCV-HoxA9-GFP* or *MSCV-Meis1a-YFP*, respectively) DNA (V) and wild-type C57BL/6 genomic DNA (G) were used as controls.

(E) Percentage of GFP/YFP⁺ cells in the bone marrow of secondary recipients untreated or treated with doxycycline at various time points following transplantation. Randomized deinduction was performed 2 weeks after transplantation (n = 2–3 recipients/time point/treatment).

(F) Percentage of blasts in the bone marrow of secondary recipients untreated or treated with doxycycline at various time-points following transplantation. Randomized deinduction was performed 2 weeks after transplantation (n = 2–3 recipients/time point/treatment). Blasts were scored on May-Grunwald-Giemsa-stained bone marrow cytopins.

See also Figure S4.




Figure 5. IDH2^{R140Q} and Fit3^{ITD} Cooperate in Leukemia Initiation

(A) Representative H&E staining of tissue sections from IDH2^{R140Q-t}/Fit3^{ITD} compound transgenic animals and an Fit3^{ITD} control animal. Compound transgenic animals develop acute myeloid (AML-like) and lymphoid (ALL-like) malignancies whereas Fit3^{ITD} animals develop myeloproliferative disease (MPD). Left panels: a compound transgenic animal diagnosed with AML-like disease. Apoptotic debris and numerous tingible body macrophages (magnified in inset, upper left panel) characteristic of highly proliferative disease are evident throughout. Infiltration of intermediate-sized blast-like immature mononuclear cells (magnified in inset, upper right panel) is evident in the red pulp of the spleen, the liver, and kidney. Middle panels: a compound transgenic animal diagnosed with ALL-like disease. T lymphoblasts (confirmed by immunohistochemical staining using anti-CD3ε antibody, not shown) with high-grade morphology are present in the thymus, spleen, liver, and lung. Numerous mitoses are present, characteristic of a rapidly proliferative disease. Right panels: MPD in an Fit3^{ITD} animal with a hypercellular bone marrow with myeloid maturation and increased myeloid cells in the spleen. Original magnification, 600×.

(legend continued on next page)

least in some contexts, are addicted to the continued function of the mutant IDH2 protein for maintenance.

Genetic Deinduction of $IDH2^{R140Q}$ Has Profound Effects on Leukemic Blasts in a Compound $IDH2^{R140Q};FIt3^{ITD}$ AML Model

We next sought to explore the function of mutant IDH2 in a system that more closely recapitulates the genetics of human AML. Internal tandem duplication in the receptor tyrosine kinase $FIt3$ is a frequent event in AML patients, is associated with poor prognosis, and co-occurs with mutations in $IDH1$ or $IDH2$ (Patel et al., 2012). Knockin $FIt3^{ITD}$ transgenic mice develop lethal myeloproliferative neoplasms (MPNs), but not overt leukemia (Chu et al., 2012; Li et al., 2008; Rau et al., 2013). Notably, combining the $FIt3^{ITD}$ allele with other mutations observed in AML patients can transform this MPN into full-blown acute leukemia (Rau et al., 2013).

To test whether the $IDH2^{R140Q}$ mutation can cooperate with $FIt3^{ITD}$ to drive disease progression, we generated compound $IDH2^{R140Q-t};FIt3^{ITD}$ animals and treated them with doxycycline. Excitingly, and in contrast to $FIt3^{ITD}$ single transgenic littermate controls, compound animals developed acute leukemias (Figures 5A and 5B). In our cohort, $IDH2^{R140Q-t};FIt3^{ITD}$ animals displayed a significantly reduced overall survival compared with $FIt3^{ITD}$ controls (median survival of 229 days versus 352 days, respectively; $p = 0.0299$, Mantel-Cox test) (Figure S5A). Consistent with previous published observations (Chu et al., 2012; Li et al., 2008; Rau et al., 2013), the MPD in $FIt3^{ITD}$ animals was characterized by a hypercellular bone marrow with myeloid predominance and maturation (Figure 5A). The leukemias that developed in compound transgenic mice, on the other hand, were characterized by infiltration of large monomorphic blasts into hematopoietic (bone marrow, spleen, thymus) and non-hematopoietic (liver, lung, kidney) organs. We analyzed bone marrow cells, splenocytes, and thymocytes by FACS and found that the immuno-phenotype of cells from different animals, and occasionally from different organs within the same animal, varied (Figure 5B). We identified leukemias that displayed both myeloid ($CD3\epsilon^{-}B220^{-}Mac1^{low}cKit^{+}$) and lymphoid ($Mac1^{-}B220^{-}CD3\epsilon^{+}CD8^{+}CD4^{-}$ and $Mac1^{-}B220^{-}CD3\epsilon^{-}CD8^{+}CD4^{+}$) markers (Figure 5B).

Our data strongly suggest that $IDH2^{R140Q}$ is a bona fide cooperating oncogene in vivo. However, in order to further confirm the malignant nature of the disease and the diagnosis of acute leukemia that developed in $IDH2^{R140Q-t};FIt3^{ITD}$ animals, we performed transplantation experiments (Kogan et al., 2002). To this end, we transplanted leukemic cells into sublethally irradiated $CD45.1^{+}$ syngeneic recipients and treated them with doxycycline. In this system, leukemic cells compete with normal recipient bone marrow cells in the niche and we were able to directly track their fate as they express the alternate surface

antigen $CD45.2$. In two independent experiments we used BM MNCs or thymocytes derived from two different compound transgenic animals (#5517 and #12063, respectively). In both instances, the leukemic cells were able to recapitulate a lethal leukemia in transplanted recipients, and notably upon transplantation they mostly lost the expression of mature lineage markers ($Mac1$ for #5517 and $CD3\epsilon$ for #12063) (Figures 5C, 5D, and S5B–S5D). The disease derived from donor #5517 was used in serial transplantation experiments and became more aggressive and homogenous, and in secondary recipients the bone marrow was composed almost exclusively of $CD45.2^{+}CD3\epsilon^{-}B220^{-}Mac1^{-}$ immature blasts.

Having established a model where mutant $IDH2$ contributes to leukemia initiation, our next step was to determine whether genetic inactivation of $IDH2^{R140Q}$ in this context had an effect on leukemia maintenance and/or progression. Due to the variable onset of disease and the time required to generate large cohorts of compound transgenic animals, we focused our efforts on a transplantation-based “chimeric” model. We used primary leukemia cells from the bone marrow of donor #5517 to perform randomized deinduction experiments. As previously, leukemic cells were allowed to engraft for 3 days in the presence of doxycycline, and then half of the recipients were taken off doxycycline food (Figure 6A). We followed animals until they became moribund and had to be euthanized. We observed no clear differences in survival of doxycycline-treated and -untreated animals across primary, secondary, or tertiary transplantation experiments. Analysis of serum 2-HG levels confirmed that the metabolite returned to baseline levels following transgene deinduction (Figure S5E). All animals that were caught prior to succumbing to disease were subjected to a detailed histopathological analysis. Infiltration of leukemic cells into nonhematopoietic organs was similar between the two treatment cohorts (Figure S5F). In contrast, there was a clear difference with respect to bone marrow involvement. The bone marrow of animals treated with doxycycline was composed predominantly of blasts whereas animals in the untreated group displayed fewer blasts and marked differentiation (Figures 6B–6E). The morphological analysis was in agreement with the percentage chimerism as assessed by $CD45.1/CD45.2$ staining. Thus, inhibition of $IDH2^{R140Q}$ in acute leukemia in the context of a cooperating $FIt3^{ITD}$ mutation, at least in some cases, results in reduced proliferation and/or differentiation of leukemic blasts.

DISCUSSION

IDH mutations have been proposed as attractive targets for the development of novel anticancer therapeutics because specific small molecule inhibitors can directly block the neomorphic activity of the enzymes, namely the production of 2-HG (Popovici-Muller et al., 2012; Wang et al., 2013). However, the

(B) Examples of FACS plots demonstrating the types of acute leukemia diagnosed in $IDH2^{R140Q-t};FIt3^{ITD}$ compound transgenic animals. Left panels: presence of $CD3\epsilon^{+}cKit^{+}$ lymphoblasts in the thymus and bone marrow; cells in the thymus are exclusively $CD8^{+}CD4^{-}$. Right panels: cells in the bone marrow are almost exclusively $Mac1^{+}/^{low}$ and a population of $Mac1^{low}cKit^{+}$ immature cells is evident; in the thymus of the same animal, $CD3\epsilon^{-}CD8^{+}$ lymphoblasts are present.

(C and D) Primary AML (BM MNCs from donor #5517) and ALL (thymocytes from donor #12063) cells recapitulate a lethal leukemia in transplanted recipients treated with doxycycline. FACS plots demonstrate the overwhelming majority of donor-derived ($CD45.2^{+}$) cells in the bone marrow of moribund recipients and the loss of lineage markers ($Mac1$ and $CD3\epsilon$, respectively) upon serial transplantation.

See also Figure S5.




Figure 6. Mutant $IDH2$ Contributes to Leukemia Initiation and Maintenance in the Context of a Cooperating $FIt3^{ITD}$ Lesion

(A) Schematic outlining the strategy for randomized deinduction experiments using AML cells from recipient #5517.

(B) May-Grunwald-Giemsa-stained bone marrow cytopspins showing presence of leukemic blasts and differentiated myeloid cells in doxycycline-treated and -untreated recipients, respectively.

(C) Examples of FACS plots showing reduced donor chimerism in untreated versus doxycycline-treated recipients based on differential staining for the cell surface markers CD45.1/CD45.2.

(D and E) Genetic deinduction of $IDH2^{R140Q}$ expression by withdrawal of doxycycline has a profound effect on the proliferation and/or differentiation of leukemic blasts in vivo. Percentage of donor-derived ($CD45.2^+$) cells (D) and blasts (E) in the bone marrow of primary, secondary, or tertiary recipients untreated or treated with doxycycline is shown. Blasts were scored on May-Grunwald-Giemsa-stained bone marrow cytopspins. Randomized deinduction was performed 3 days after transplantation.

(F) Model for the role of $IDH2^{R140Q}$ in primary HSPCs and in the maintenance of leukemia.

See also Figure S5.

contribution of mutant IDH proteins to transformation in vivo remains poorly understood, and importantly, whether or not cancer cells are addicted to 2-HG in their native niche for growth and/or maintenance is yet to be determined.

We have generated a mouse model of $IDH2^{R140Q}$, the most common $IDH2$ mutation observed in human AML. To our knowledge this is the first transgenic allele of mutant $IDH2$

reported to date. In our model, expression of the transgene and the consequent production of 2-HG is on/off inducible and comparable to that observed in AML patients, providing a valuable system for evaluating the biological effects of deinduction as well as the pharmacological efficacy of potential 2-HG inhibitors. Consistent with what was previously reported for a knockin model of $IDH1^{R132H}$ (Sasaki et al., 2012), we found that

expression of mutant *IDH2* resulted in alterations within the hematopoietic compartment characterized by an expansion of HSPCs within the spleen and bone marrow, but on its own it was not sufficient for leukemogenesis, at least within the time frame of our experiment.

In a well-established multilineage differentiation assay, *IDH2*^{R140Q-t} KSL cells formed a greatly reduced number of erythroid colonies, but an equivalent number of myeloid colonies, in comparison with controls. We established a transcriptional signature associated with this block of erythroid differentiation and identified downregulation of GATA1 activity and upregulation of the hypoxia and TNF- α pathways as being potentially important in this process. Inhibition of GATA1 function was previously reported in mutant *IDH* AML patients (Figueroa et al., 2010). The effects of mutant IDH proteins on the hypoxia pathway have been disputed with some studies reporting hyperactivation (Xu et al., 2011) and others reporting inactivation (Koivunen et al., 2012; Losman et al., 2013), albeit in different systems. In our model, the observed transcriptional changes strongly argue in favor of activation of hypoxic signaling. Importantly, both the block of differentiation and the altered transcriptional profile in *IDH2*^{R140Q-t} cells is reversible by the mutant IDH2 inhibitor AGI-6780. Our results confirm and expand on previous studies showing that mutant IDH proteins can induce a reversible block of differentiation in the erythroid leukemia line TF-1 (Losman et al., 2013; Wang et al., 2013). We conclude that at least under some conditions, production of 2-HG by mutant IDH proteins may not only block differentiation of hematopoietic cells, it may in fact bias it toward the myeloid lineage.

Though studies on the effects of *IDH* mutations on primary and leukemic cells in vitro or on HSPC function and lineage development in vivo provide important mechanistic insights, they fail to answer the most crucial question of whether mutant *IDH2* is required for leukemia initiation and maintenance in vivo in the presence of a functional niche. To address this, we used two compound transgenic models in which *IDH* mutation was combined with activation of additional oncogenes. *HoxA9* and *Meis1a* are downstream targets of numerous pathways deregulated in AML and forced coexpression of these two proteins is sufficient to transform murine HSPCs (Kroon et al., 1998; Wang et al., 2010). Notably, when this powerful combination was introduced into *IDH2* mutant KSL cells, the proliferation and/or maintenance of the resultant leukemic cells were dependent on continued expression of *IDH2*^{R140Q}. Within 2 weeks of genetic deinduction of mutant *IDH*, we observed evidence of differentiation, and 2 weeks later, 6/8 animals showed complete remission with elimination of any detectable leukemic cells. Interestingly, we found that *Atf3*, which has been implicated as a positive regulator of TGF- β signaling and was shown to enhance cancer-initiating cell activity in breast cancer cells, was downregulated upon *IDH2*^{R140Q} inactivation (Yin et al., 2010). Our results are both surprising and encouraging in that we have modeled a situation where *IDH* mutation occurs as an early event and leukemic transformation occurs as a result of subsequent genetic “hits.” Indeed, *IDH* mutation is considered an early event in the evolution of AML as well as other cancer types including glioma (Kandoth et al., 2013; Watanabe et al., 2009). Thus our results strongly suggest that *IDH* mutation may

establish a state of oncogene addiction even in a genetic setting where mutant *IDH* is not required for cancer initiation.

By generating compound *IDH2*^{R140Q};*FIt3*^{ITD} transgenic mutants, we demonstrated that *IDH2*^{R140Q} cooperates with *FIt3*^{ITD} in leukemia initiation in vivo, strongly suggesting that *IDH* mutations are cooperative tumorigenic drivers in AML. Our results are coherent with two recent studies demonstrating that retroviral transduction of *IDH* mutations into mouse bone marrow cells can cooperate with other oncogenic stimuli in leukemogenesis (Chaturvedi et al., 2013; Chen et al., 2013). Retroviral models, though highly useful, are limited by numerous factors including artificial levels of transgene expression and random integration of the provirus into the genome. Our transgenic approach demonstrates the additional requirements and consequences of mutant *IDH* expression at physiologically relevant levels, as well as those of mutant *IDH* deinduction in vivo. Indeed the latency of disease development in *IDH2*^{R140Q};*FIt3*^{ITD} mice suggests that additional mutations were required for full leukemic transformation. Recent sequencing efforts by the Cancer Genome Atlas have revealed that the median number of recurrent mutations in adult normal karyotype AML is approximately five (Cancer Genome Atlas Research Network, 2013). The spectrum of disease that developed in different transgenic animals in our model may be explained by the nature of additional mutations or by the type of cell in which they occurred. Indeed, numerous transgenic models develop different types of hematopoietic malignancies among animals of the same genotype (Rau et al., 2013; Yilmaz et al., 2006).

As with our *HoxA9/Meis1a* transduction model, we observed that genetic inactivation of mutant *IDH2* in the context of a cooperating *FIt3*^{ITD} lesion had an effect on disease progression, and though we were unable to show increased survival upon mutant *IDH2* deinduction, we did demonstrate effects on the proliferation and/or differentiation of leukemic blasts. Analysis of leukemic infiltrates suggested that in this highly aggressive setting, mice that display a response in the bone marrow may nonetheless succumb to the disease due to damage of nonhematopoietic organs. Additionally, because a reduction in 2-HG levels may take some time (based on our measurements in nonleukemic mice 2 weeks after deinduction), leukemic cells may cause irreparable damage to the bone marrow niche and/or to other organs before the cells are eliminated. If that is the case, inhibition of mutant IDH proteins may synergize with chemotherapy or other drugs (in this case *FIt3* inhibitors) that produce more immediate effects.

In summary, our findings, and those of other groups (Losman et al., 2013; Rohle et al., 2013; Wang et al., 2013), prove that at least some of the effects of *IDH* mutation are dependent on continued production of 2-HG. Critically, we extend previous work by demonstrating that those effects are reversible in vivo and addicted to the proto-oncogenic activity of the IDH mutant enzyme even in a genetic milieu where leukemia initiation is *IDH* mutant independent. We therefore validate mutant IDH proteins as very strong candidates for continued development of targeted anticancer therapeutics. Our model can serve as an invaluable tool for evaluating the biological effects of genetic deinduction of *IDH* mutations in various genetic settings as well as the pharmacological efficacy of potential mutant IDH2

inhibitors either alone or in combination with other compounds (Figure 6F).

EXPERIMENTAL PROCEDURES

Transgenic Animals

The tetracycline-inducible *IDH2^{R140Q}* allele was created following the scheme shown in Figure 1A and backcrossed into the C57BL/6 background (see Supplemental Experimental Procedures for more information). *ROSA26-M2* (Hochedlinger et al., 2005), C57BL/6, and CD45.1⁺ (B6.SJL-*Ptprc^a Pepc^b*/BoyJ) animals were purchased from Jackson Laboratories. *Flt3^{TD}* transgenic (Li et al., 2008) animals were kindly provided by Donald Small and Patrick Brown from Johns Hopkins University School of Medicine (Baltimore). To activate transgene expression in vivo, a doxycycline-containing chow (Harlan Laboratories) was administered to animals at the time of weaning (~3 weeks of age). To deactivate transgene expression, mice were taken off the doxycycline-containing diet and placed on a regular laboratory rodent diet. We obtained approval for all animal experiments from the Beth Israel Deaconess Medical Center IACUC Committee on Animal Research (Protocol #066-2011; Approved 08/15/2011).

CFU-GEMM Assays

CFU-GEMM assays were performed using MethoCult GF M3434 (StemCell Technologies) in accordance with the manufacturer's instructions. Briefly, KSL cells from control and *IDH2^{R140Q-t}* mice were isolated by FACS using a BD FACSAria IIu sorter (Becton Dickinson) (see Supplemental Experimental Procedures) and 900 cells were added to individual 3 ml aliquots of MethoCult GF M3434. One microgram per milliliter doxycycline and five micromolar AGI-6780 (Wang et al., 2013) were added as indicated. Cells were then plated at a density of 300 cells/dish in duplicate for each biological replicate and cultured for 7 days at 37°C and 5% CO₂. Colonies were scored in a 2.5 cm × 2.5 cm area in the center of each dish using a grid. For the replating experiment, cells were collected in IMDM media supplemented with 2% fetal bovine serum (FBS), washed once in PBS, counted, and replated in MethoCult GF M3434 supplemented with 1 μg/ml doxycycline at a density of 5,000 cells/dish. Colonies were counted after 7–14 days of culture as above.

Generation of the *HoxA9/Meis1a* Transduction Model

KSL cells were sorted (see Supplemental Experimental Procedures) from *IDH2^{R140Qhmn-t}* mice that had been treated with doxycycline for 6 weeks. Cells were cultured for 8 hr in StemSpan serum free expansion medium (StemCell Technologies) supplemented with murine SCF, TPO, IL-3, IL-6, and Flt3-L (PeproTech) on Retronectin-coated (Takara Bio) petri dishes. Cells were transduced overnight using *MSCV-HoxA9-GFP* and *MSCV-Meis1a-YFP* (kindly provided by Dr. Christian Bach). The next day, cells were harvested and washed twice with phosphate buffered saline (PBS). Viable cells were counted following trypan blue staining and 5,000 cells were injected retro-orbitally into sublethally irradiated (6.5Gr) C57BL/6 recipients. For the initial experiment, secondary transplantation and randomized deinduction was performed as outlined in Figure 4A. For the repeat experiment, all recipients were maintained on doxycycline food for 2 weeks, at which time 2 recipients were analyzed to confirm presence of GFP/YFP⁺ cells in the bone marrow. Randomized deinduction was then performed with recipients randomly assigned to doxycycline-treated or untreated groups. Mice were then analyzed every 2 weeks to monitor the kinetics of disease regression.

Serial Transplantation of *IDH2^{R140Q-t}/Flt3^{TD}* Leukemic Cells

Bone marrow cells extracted from the femurs and tibias of a compound transgenic animal diagnosed with AML were subjected to red blood cell (RBC) lysis using ACK lysis buffer (GIBCO), washed twice with PBS supplemented with 2% FBS, passed through a 70 μm strainer, and frozen in FBS supplemented with 10% dimethyl sulfoxide (DMSO). On the day of transplantation, cells were thawed at 37°C and washed twice in PBS. Viable cells were counted following trypan blue staining. A hundred thousand donor cells were injected retro-orbitally into sublethally irradiated (6.5Gr) CD45.1⁺ recipients. Alternatively, 10⁵ donor cells were mixed with 5 × 10⁵ wild-type CD45.1⁺ competitor

cells and injected retro-orbitally into lethally irradiated (9.5Gr) CD45.1⁺ recipients. For serial transplantations, the process was repeated using 10⁵ cells from primary or secondary doxycycline-treated recipients.

Microarray Analysis

KSL cells from control and *IDH2^{R140Q-t}* mice were cultured for 3 days in MethoCult GF M3434 (StemCell Technologies) supplemented with 1 μg/ml doxycycline. All cells were then collected and total RNA was extracted using Trizol (Ambion) with GlycoBlue (Life Technologies) as a carrier. Two-hundred nanograms of RNA was hybridized to Affymetrix Mouse Gene 2.1 ST arrays by the Beth Israel Deaconess Medical Center Genomics and Proteomics Core. The obtained raw intensity .cel files were normalized by robust multichip analysis (Bioconductor release 2.12) and differential expression was determined using the limma Bioconductor package by fitting a linear model. Gene set enrichment analysis was conducted with the gene sets from the Molecular Signatures Database (MolSigDB v3.1) (see Supplemental Experimental Procedures and Table S4 for more information).

SUPPLEMENTAL INFORMATION

Supplemental Information for this article includes Supplemental Experimental Procedures, five figures, and four tables and can be found with this article online at <http://dx.doi.org/10.1016/j.stem.2013.12.016>.

ACKNOWLEDGMENTS

We thank Dr. Robert Welner, Dr. Christian Bach, and members of the Pandolfi laboratory for critical discussion. L.M.K. was supported by an Overseas Postdoctoral Fellowship from the National Health and Research Council of Australia. M.R. was supported by the German Academy of Sciences Leopoldina (Leopoldina Research Fellowship grant number: LPDS 2009-27). R.T. was supported by a Marie Curie International Outgoing Fellowship for Career Development. K.Y., M.S., and K.S. are employees and shareholders of Agios Pharmaceuticals.

Received: August 5, 2013

Revised: November 13, 2013

Accepted: December 24, 2013

Published: January 16, 2014

REFERENCES

- Amary, M.F., Bacsi, K., Maggiani, F., Damato, S., Halai, D., Berisha, F., Pollock, R., O'Donnell, P., Grigoriadis, A., Diss, T., et al. (2011). IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. *J. Pathol.* 224, 334–343.
- Beard, C., Hochedlinger, K., Plath, K., Wutz, A., and Jaenisch, R. (2006). Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. *Genesis* 44, 23–28.
- Cancer Genome Atlas Research Network (2013). Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N. Engl. J. Med.* 368, 2059–2074.
- Chaturvedi, A., Araujo Cruz, M.M., Jyotsana, N., Sharma, A., Yun, H., Görlich, K., Wichmann, M., Schwarzer, A., Preller, M., Thol, F., et al. (2013). Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. *Blood* 122, 2877–2887.
- Chen, C., Liu, Y., Lu, C., Cross, J.R., Morris, J.P., 4th, Shroff, A.S., Ward, P.S., Bradner, J.E., Thompson, C., and Lowe, S.W. (2013). Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. *Genes Dev.* 27, 1974–1985.
- Chu, S.H., Heiser, D., Li, L., Kaplan, I., Collector, M., Huso, D., Sharkis, S.J., Stem, C., and Small, D. (2012). FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm. *Cell Stem Cell* 11, 346–358.

- Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M., Fantin, V.R., Jang, H.G., Jin, S., Keenan, M.C., et al. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature* **462**, 739–744.
- Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H.F., et al. (2010). Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell* **18**, 553–567.
- Fisher, G.H., Wellen, S.L., Klimstra, D., Lenczowski, J.M., Tichelaar, J.W., Lizak, M.J., Whitsett, J.A., Koretsky, A., and Varmus, H.E. (2001). Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. *Genes Dev.* **15**, 3249–3262.
- Fujiwara, Y., Browne, C.P., Cunniff, K., Goff, S.C., and Orkin, S.H. (1996). Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1. *Proc. Natl. Acad. Sci. USA* **93**, 12355–12358.
- Gross, S., Cairns, R.A., Minden, M.D., Driggers, E.M., Bittinger, M.A., Jang, H.G., Sasaki, M., Jin, S., Schenkein, D.P., Su, S.M., et al. (2010). Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. *J. Exp. Med.* **207**, 339–344.
- Hochedlinger, K., Yamada, Y., Beard, C., and Jaenisch, R. (2005). Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. *Cell* **121**, 465–477.
- Kandoth, C., McLellan, M.D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J.F., Wyczalkowski, M.A., et al. (2013). Mutational landscape and significance across 12 major cancer types. *Nature* **502**, 333–339.
- Kang, M.R., Kim, M.S., Oh, J.E., Kim, Y.R., Song, S.Y., Seo, S.I., Lee, J.Y., Yoo, N.J., and Lee, S.H. (2009). Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. *Int. J. Cancer* **125**, 353–355.
- Kogan, S.C., Ward, J.M., Anver, M.R., Berman, J.J., Brayton, C., Cardiff, R.D., Carter, J.S., de Coronado, S., Downing, J.R., Fredrickson, T.N., et al.; Hematopathology subcommittee of the Mouse Models of Human Cancers Consortium (2002). Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. *Blood* **100**, 238–245.
- Koivunen, P., Lee, S., Duncan, C.G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J.A., Joensuu, P., Bergmann, U., Gross, S., et al. (2012). Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. *Nature* **483**, 484–488.
- Kroon, E., Krosl, J., Thorsteinsdottir, U., Baban, S., Buchberg, A.M., and Sauvageau, G. (1998). Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. *EMBO J.* **17**, 3714–3725.
- Li, L., Piloto, O., Nguyen, H.B., Greenberg, K., Takamiya, K., Racke, F., Huso, D., and Small, D. (2008). Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. *Blood* **111**, 3849–3858.
- Losman, J.A., Looper, R., Koivunen, P., Lee, S., Schneider, R.K., McMahon, C., Cowley, G., Root, D., Ebert, B.L., and Kaelin, W.G. (2013). (R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible. *Science* **339**, 1621–1625.
- Mardis, E.R., Ding, L., Dooling, D.J., Larson, D.E., McLellan, M.D., Chen, K., Koboldt, D.C., Fulton, R.S., Delehaunty, K.D., McGrath, S.D., et al. (2009). Recurring mutations found by sequencing an acute myeloid leukemia genome. *N. Engl. J. Med.* **361**, 1058–1066.
- Parsons, D.W., Jones, S., Zhang, X., Lin, J.C.-H., Leary, R.J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G.L., et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. *Science* **321**, 1807–1812.
- Patel, J.P., Gönen, M., Figueroa, M.E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012). Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *N. Engl. J. Med.* **366**, 1079–1089.
- Popovici-Muller, J., Saunders, J.O., Salituro, F.G., Travins, J.M., Yan, S., Zhao, F., Gross, S., Dang, L., Yen, K.E., Yang, H., et al. (2012). Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo. *ACS Med. Chem. Lett.* **3**, 850–855.
- Rau, R., Magoon, D., Greenblatt, S., Li, L., Annesley, C., Duffield, A.S., Huso, D., McIntyre, E., Clohessy, J.G., Reschke, M., et al. (2013). NPMc+ cooperates with FLT3/ITD mutations to cause acute leukemia recapitulating human disease. *Exp. Hematol.*, in press. Published online October 29, 2013. <http://dx.doi.org/10.1016/j.exphem.2013.10.005>.
- Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013). An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. *Science* **340**, 626–630.
- Sasaki, M., Knobbe, C.B., Munger, J.C., Lind, E.F., Brenner, D., Brüstle, A., Harris, I.S., Holmes, R., Wakeham, A., Haight, J., et al. (2012). IDH1(R132H) mutation increases murine hematopoietic progenitors and alters epigenetics. *Nature* **488**, 656–659.
- Wang, Y., Krivtsov, A.V., Sinha, A.U., North, T.E., Goessling, W., Feng, Z., Zon, L.I., and Armstrong, S.A. (2010). The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. *Science* **327**, 1650–1653.
- Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernysky, A., Liu, W., Gliser, C., et al. (2013). Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. *Science* **340**, 622–626.
- Ward, P.S., Patel, J., Wise, D.R., Abdel-Wahab, O., Bennett, B.D., Collier, H.A., Cross, J.R., Fantin, V.R., Hedvat, C.V., Perl, A.E., et al. (2010). The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α -ketoglutarate to 2-hydroxyglutarate. *Cancer Cell* **17**, 225–234.
- Watanabe, T., Nobusawa, S., Kleihues, P., and Ohgaki, H. (2009). IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. *Am. J. Pathol.* **174**, 1149–1153.
- Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011). Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α -ketoglutarate-dependent dioxygenases. *Cancer Cell* **19**, 17–30.
- Yilmaz, Ö.H., Valdez, R., Theisen, B.K., Guo, W., Ferguson, D.O., Wu, H., and Morrison, S.J. (2006). Pten dependence distinguishes hematopoietic stem cells from leukaemia-initiating cells. *Nature* **441**, 475–482.
- Yin, X., Wolford, C.C., Chang, Y.-S., McConoughey, S.J., Ramsey, S.A., Aderem, A., and Hai, T. (2010). ATF3, an adaptive-response gene, enhances TGF β signaling and cancer-initiating cell features in breast cancer cells. *J. Cell Sci.* **123**, 3558–3565.